Hims & Hers Health Inc. (NYSE:HIMS) posted its third-quarter fiscal 2026 results after Monday’s closing bell, missing the Street’s expectations on the top and bottom lines.  

• HIMS stock is moving. Watch the price action here.

Hims & Hers Q3 Details       

Hims & Hers Health reported quarterly losses of 14 cents per share, which missed the analyst estimate of earnings of eight cents, per Benzinga Pro data. 

Quarterly revenue of $890.37 million missed the Street estimate of $892.89 million, but was up from $598.98 million in the same period last year.

Subscribers grew to nearly 2.8 million, up 13% year-over-year.

Hims & Hers also announced the appointment of Andrew Huberman, Ph.D., to the company’s board of directors.

“In health care, whoever owns the customer relationship wins, and that’s exactly what we’re building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them,” said Andrew Dudum, co-founder and CEO.

Looking Ahead

Hims & Hers Health expects fourth-quarter revenue in a range of $875 million to $895 million, versus the $953.45 million analyst estimate.

The company narrowed its fiscal 2026 revenue outlook to between $3.13 billion and $3.15 billion, versus the $3.21 billion estimate.

HIMS Stock Price: According to data from Benzinga Pro, Hims & Hers stock was down 1.26% to $22.57 in Monday’s extended trading.  

Photo: Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.